An estimated
will live with dementia by 2050
A new case every
somewhere in the world
Globally,
in healthcare expenditure by 2050
We are pioneers of digital Cognitive Stimulation Therapy (CST), the world’s leading non-drug dementia treatment. Alzheimer’s Disease International and the WHO recommend its global implementation and endorsed by the National Institute for Health and Care Excellence (NICE) in the UK.
We are pioneers of digital Cognitive Stimulation Therapy (CST), the world-leading non-drug dementia treatment recommended for global implementation and endorsed by the National Institute for health and Care Excellence (NICE) in the UK.
4-6 months delay in cognitive decline
Enhanced communication and language skills
Improved confidence and quality of life
Meet Ayla
your CST Assistant
Our first Ayla Dementia Care platform product. Offers accessible, customizable and expertly validated digital CST to support standardized high quality treatment delivery.
*based on DK and AgeUK usability study
Learn how Ayla can help you and your organisation offer engaging, adaptable and clinically relevant Cognitive Stimulation Therapy (CST)
Help us in the development of our Home Companion, the first product directly aimed to help people with dementia. The Home Companion will assist you or a loved one in cognitive stimulation and living with dementia.
Stay updated on Brain+ company releases, financials and corporate actions as we build our digital dementia care platform.
Brain+ A/S
Købmagergade 53, 3rd floor
DK-1150 Copenhagen
Company Reg: 36439440